MetaCap

Cerus (CERS) vs Senseonics (SENS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Senseonics (SENS) has outperformed Cerus (CERS) over the past year, gaining 49.9% versus a gain of 14.2%. Over five years, CERS leads with a -73.5% price change compared with -87.6% for SENS. Senseonics is the larger company by market cap ($439.3 million vs $373.6 million), about 1.2 times the size.

Cerus converts more of its revenue into profit, with a net margin of -6.7% versus -196.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CERS+14.20%SENS+49.91%
+109%+47%-15%
Nov 21, 20251 yearNov 20, 2026
CERS-74.31%SENS-88.48%
+5%-47%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CERS versus SENS key metrics
MetricCERSSENS
Share price$1.85$8.02
Market cap$373.62M$439.34M
1-day change-2.63%-9.94%
YTD return-10.19%+45.29%
1-year return+14.20%+49.91%
5-year return-73.50%-87.59%
Forward P/E123.33—
EPS (TTM)$-0.04$-2.27
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$233.80M$35.26M
Revenue growth (YoY)+16.13%+56.89%
Net income (latest FY)$-15.63M$-69.10M
Gross margin—44.71%
Operating margin-3.71%-193.83%
Net margin-6.68%-195.99%
52-week high$3.47$13.98
52-week low$1.59$4.79
Distance from 52-week high-46.69%-42.62%
Analyst consensusstrong_buybuy
Avg. price target upside+177.30%+88.03%
Average volume2.12M821.73K
Shares outstanding201.95M54.78M
Employees261130
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SENS has outperformed CERS by 35.7 percentage points over the past year.
  • Cerus is more profitable, keeping -6.7 cents of every revenue dollar as net income versus -196.0 cents for Senseonics.
  • Senseonics grew revenue faster in its latest fiscal year (+56.89% vs +16.13%).

About Cerus

CERS stock →

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Health Care · Medical/Dental Instruments · 261 employees

About Senseonics

SENS stock →

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.

Health Care · Medical/Dental Instruments · 130 employees

CERS vs SENS FAQ

Which is bigger, Cerus or Senseonics?

Senseonics (SENS) is larger, with a market capitalization of $439.34M compared with $373.62M for Cerus (CERS).

Which stock has performed better over the past year, CERS or SENS?

SENS returned +49.91% over the past 12 months, compared with +14.20% for CERS (price return, excluding dividends). Past performance does not predict future results.

Are Cerus and Senseonics in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons